header logo image


Page 853«..1020..852853854855..860870..»

AIVITA Biomedical to Present at Upcoming Regenerative Medicine, Oncology and Investor Conferences in November – PRNewswire

November 3rd, 2019 12:45 am

IRVINE, Calif., Nov. 1, 2019 /PRNewswire/ --AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, today announced that it will be presenting at the following regenerative medicine and investor conferences in November:

Society for the Immunotherapy of Cancer (SITC) Annual MeetingOral PresentationPresenter: Dr. Daniela Bota, MD, PhD, University of California, Irvine; AIVITA GBM Principal InvestigatorTitle: Phase II trial of therapeutic vaccine consisting of autologous dendritic cells loaded with autologous tumor cell antigens from self-renewing cancer cells in patients with newly diagnosed glioblastomaTime: November 6-10, 2019Location: Gaylord National Hotel & Convention Center, National Harbor, MD

The Regenerative Medicine Consortium of the Gulf Coast Consortia for Biomedical SciencesOral Presentation Presenter: Dr. Hans S. Keirstead, AIVITA Chairman and CEOTitle: Clinical and Commercial Application of Scaled Human Stem Cell DerivatesTime: November 8, 4:00 PM CTLocation: Bioscience Research Collaborative, Houston, TX

NYC Oncology Investor ConferenceOral Presentation Presenter: Dr. Hans S. Keirstead, AIVITA Chairman and CEO Title: AIVITA Corporate PresentationTime: November 12, 4:50 PM - 5:10 PMLocation: Rockefeller Center, New York, NY

Society for NeuroOncology Annual MeetingPoster PresentationTitle: Phase II trial of AV-GBM-1 (autologous dendritic cells loaded with autologous tumor associated antigens) as adjunctive therapy following primary surgery plus concurrent chemoradiation in patients with newly diagnosed glioblastoma.Time: November 20-24, 2019Location: JW Marriott Desert Ridge, Phoenix, AZ

About AIVITA Biomedical

AIVITA Biomedical is a privately held company engaged in the advancement of commercial and clinical-stage programs utilizing curative and regenerative medicines. Founded in 2016 by pioneers in the stem cell industry, AIVITA Biomedical utilizes its expertise in stem cell growth and directed, high-purity differentiation to enable safe, efficient and economical manufacturing systems which support its therapeutic pipeline and commercial line of skin care products. All proceeds from the sale of AIVITA's skin care products support the treatment of women with ovarian cancer.

SOURCE AIVITA Biomedical, Inc.

Homepage

See original here:
AIVITA Biomedical to Present at Upcoming Regenerative Medicine, Oncology and Investor Conferences in November - PRNewswire

Read More...

Thought Leadership & Innovation Foundation to Expand Its Regenerative Medicine Program Through New Collaboration with RenovaCare – Business Wire

November 3rd, 2019 12:45 am

MCLEAN, Va.--(BUSINESS WIRE)--The Thought Leadership & Innovation Foundation (TLI) announces today plans to build on its existing Regenerative Medicine Program through a research collaboration with cellular therapy industry leader RenovaCare. As part of TLIs efforts to conduct vital research in regenerative medicine and chronic disease, this initiative aims to innovate methods for reducing complications from burn and diabetic wounds across large populations.

Our research base, collaborative institutions and long history of innovation align with RenovaCares commitment to breakthrough biomedical technologies, says Bill Oldham, founder and chairman of the Board, TLI. The patented RenovaCare SkinGun technology and its ability to ultra-gently spray stem cells could present a special opportunity for investigations and applications in a wide range of regenerative therapies. Working together, our overall goal is to improve the quality, efficiency and effectiveness of patient care by not only developing new treatment methods, but also by making thoughtful and systematic changes to healthcare and health systems.

TLIs Regenerative Medicine program seeks to adapt new strategies based upon sound scientific evidence, utilizing its infrastructure to support the continuation of scientific and medical work, as well as the development of grant-funded research and other initiatives.

Dr. Robin A. Robinson, who is a TLI Fellow, Vice President of Scientific Affairs, RenovaCare, and named one of the top 100 innovators in medicine by Medicine Maker in 2018, states, This exciting collaboration between RenovaCare and TLIs Regenerative Medicine Program is the first step toward the development of meaningful and quality therapeutic treatments that will benefit patients around the world.

About TLI Foundation:

TLI Foundation is a nonprofit foundation focused on driving innovative thinking and action on global issues relating to health, education and economic empowerment. The organization is committed to fostering transformative change and improving the health and well-being outcomes of communities around the world. Visit https://www.thoughtfoundation.org/

About RenovaCare:

RenovaCare, Inc. is a biotechnology company focused on developing first-of-their-kind autologous (self-donated) stem cell therapies for the regeneration of human organs. Initial products under development target the bodys largest organ, the skin. Investigative clinical use of their flagship technology has shown to be promising new alternatives for patients suffering from burns, and chronic and acute wounds. https://www.renovacareinc.com.

Originally posted here:
Thought Leadership & Innovation Foundation to Expand Its Regenerative Medicine Program Through New Collaboration with RenovaCare - Business Wire

Read More...

New Alzheimer Treatment Could Take The Brakes Off The Bodys Repair Systems Allowing It To Repair Itself – Forbes

November 3rd, 2019 12:45 am

A regenerative medicine company in Vancouver, British Columbia will begin Phase 1 studies in early 2020 for a treatment for nerve damage and degenerative diseases including Alzheimers disease.

NervGen Pharma wants to advance its proprietary therapeutic technology platform, currently in development for spinal cord injury and multiple sclerosis (MS), to generate new treatments for Alzheimer's disease.

The essence of our technology is that it takes the brakes off the bodys repair systems and allows the nervous system to repair itself, said Bill Radvak, the companys executive chairman and co-founder. You can think of it as the bodys nervous system has a housekeeping function that is constantly at work, fixing bad connections with new ones and tidying up redundant ones.

Digital

In a nutshell, the body produces a scar at sites of physical injury such as a spinal cord injury as well as sites of inflammatory damage from neurodegenerative diseases such as multiple sclerosis and Alzheimer's disease. The purpose of the scar is to encapsulate the site of the injury to prevent further damage but it ultimately inhibits the body's reparative mechanisms.

The co-inventor of NervGen's technology, Dr. Jerry Silver, Professor of Neurosciences at Case Western Reserve University's School of Medicine in Cleveland, Ohio, discovered that a component of these scars, a protein called CSPG, inhibits the body's natural ability to regrow and regenerate. NervGen's technology platform removes this inhibition and, via multiple endogenous repair mechanisms, unlocks the nervous system's ability to repair itself in a manner adapted to the site of injury and type of disease, Radvak said. Numerous repair mechanisms, including regeneration, plasticity and remyelination, have been observed in the various animal models such as stroke, spinal cord injury, multiple sclerosis, cardiac arrhythmia and peripheral nerve injury as reported in over a dozen peer reviewed papers.

In the injured state, the new nerves get stuck because the amount of CSPGs increase, and they bind to a receptor called PTPsigma, which is found on nerves, pinning them in place, Radvak explained.

NervGens core technology targets the protein tyrosine phosphatase sigma (PTP), a neural receptor that impedes nerve regeneration. Inhibition of this receptor has been shown to promote regeneration of damaged nerves and improvement of nerve function in animal models for various medical conditions, Radvak said.

NervGen has identified a series of receptor antagonistsdrugs that block or dampen biological response by binding to and blocking a receptor rather than activating it (think beta blockers)including its lead candidate, dubbed the NVG-291 compound, that they say is ready for clinical development. NervGen has been studying the compound to treat spinal cord injury. Now they want to identify other diseases for its use, including Alzheimers.

Our molecules unstick nerves and prevent new ones from getting stuck, he said. This same receptor, PTPsigma, is also found on myelin, or to be more scientifically correct, on OPCs [Oligodendrocyte progenitor cells] which develop into myelin. So, our treatment allows the myelin, which is damaged in MS, to repair itself.

Radvak said NervGen is hopeful the treatment will work in Alzheimers due to the nature of the disease itself. You also find the same problem in Alzheimers diseaseCSPGs are found in the plaques associated with the disease. We are hoping that our treatments can help the body remove the plaques and then allow new nerve connections to regrow. If our theory is correct, we hope that this could one day prevent and even reverse the disease and its terrible effects.

Alzheimer's disease is a progressive neurodegenerative disorder that destroys memory and cognitive functions. Scientists and others estimate 30 million people are affected by the disease globally including 5.8 million in the United States alone. Experts say, by 2025, the number of seniors with Alzheimer's disease could reach 7.1 million, and the prevalence of Alzheimer's disease could reach 13.8 million by 2050. The estimated cost in 2019 of caring for Americans with Alzheimer's disease and other dementias is $277 billion, a number that does not include unpaid caregiving. Of that amount, $186 billion is the cost to Medicare and Medicaid, and $60 billion is for out-of-pocket costs. Alzheimer's disease is currently ranked as the sixth leading cause of death in the United States, but recent estimates indicate that the disease may rank third, just behind heart disease and cancer, as a cause of death for seniors.

As Alzheimers research and development efforts have failed to produce new effective treatments in the last fifteen years, the medical community and pharmaceutical industry are seeking technologies with new approaches through new targets and pathways.

For example, earlier this year drug companies, Biogen and Eisai, announced they were scrapping two phase 3 trials of the investigational anti-amyloid agent aducanumab for Alzheimer's disease based on an interim futility analysis, Medscape reported this week, but in a surprising about-face, new data from the studies mean the drug is back on the table.

A statement released by the drug's manufacturers said a new analysis from the EMERGE trial shows that the drug actually met the primary endpoint of significant reduction in clinical decline, including cognition and function. In the ENGAGE trial, the cohort of patients who received a high dose of aducanumab support the findings from EMERGE, Medscape reported. They note that after consulting with the US Food and Drug Administration (FDA), regulatory approval for the drug is back on track and will be pursued.

"NervGen's platform technology introduces a truly novel approach to treating Alzheimer's disease," George Perry, PhD, said in a statement. Perry is the current editor-in-chief for the Journal of Alzheimer's Disease and professor of biology and Semmes Distinguished University Chair in neurobiology at the University of Texas at San Antonio.. "Work that began in the early 90s has confirmed the importance of the biological effect of proteoglycans in the central nervous system. In particular, the ability to shift microglia from the inflammatory phase to the phagocytic or housekeeping phase, as evidenced in both a spinal cord injury and multiple sclerosis model, is promising as it is the natural reparative process for removal of amyloid plaques. This demonstration of an immunomodulatory effect on the microglia will be of specific interest in the quest for a solution to Alzheimer's disease as the function of the microglia is one of the hot topics in this still evolving story."

Dr. Ernest Wong, NervGen's president and CEO said in a statement the Phase 1a study will be followed by a Phase 1b on subsets of both chronic and sub-acute spinal cord patients and a Phase 2 study on multiple sclerosis in 2021. Chondroitin sulfate proteoglycans (CSPGs} are intimately associated with senile plaques and our work with PTP knockout mice and other data with chondroitinase all suggest a pivotal role for PTP in AD, he said.

NervGen has taken this discovery into industrial development and is turning the platform into drugs to be developed, Radvak said. The NervGen programs are by far the most advancedwe are unaware of anyone else working with this approach. The company also has a number of patents which gives it exclusivity on this scientific approach. If we are successful and get the products to market, they would be a radically different treatment and first-in-class.

And though drug development takes time and several steps, Radvak said he is hopeful a treatment will be available soon. We are about to a big step by starting the first human trials, he said. The Company plans to submit an Investigational New Drug application with the U.S. Food and Drug Administration for NVG-291 with the intention of initiating a Phase 1 human clinical trial on healthy subjects in early 2020 and expansion of that trial in the second half of 2020 to include a cohort of spinal cord injury patients. In addition, NervGen intends to commence a Phase 2 multiple sclerosis clinical trial in early 2021.

This process takes a number of years for the product to get to market but drug development is like a relay race, he continued. Smaller companies develop drugs in the early steps and often hand over to Pharma for late stage development. At this handover, the company or product is sold to the Pharma which has increased capabilities to commercialize.

More here:
New Alzheimer Treatment Could Take The Brakes Off The Bodys Repair Systems Allowing It To Repair Itself - Forbes

Read More...

Global Regenerative Medicine Market 2019 Worldwide Industry Analysis to 2024 – Top News Herald

November 3rd, 2019 12:45 am

Global Regenerative Medicine Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024 is the most important research for who looks for complete information about the Regenerative Medicine market. The report takes a critical look at the business regulatory framework, technological advances in associated industries, and strategic approaches. For market demand, size, trading, supply, competitors, and prices as well as global predominant vendors information, the report covers all information on the global and regional markets including old and future trends. The research study also explains upcoming industry supply, market demand, value, application, type, share, competition and its analysis of key players with industry forecast from 2019 to 2024.

The research report commits different factors affecting Regenerative Medicine industry such as past data and market trends, technological advancements, upcoming innovations, market risk factors, market restraints, and challenges in the industry. The study then describes the drivers and restraints for the market along with the impact they have on the demand over the forecast period. It also observes the latest trends and development plans, patterns, and policies observed in the global market.

DOWNLOAD FREE SAMPLE REPORT: https://marketandresearch.biz/sample-request/91858

This report includes the following top vendors in terms of company basic information, product category, sales (volume), revenue (Million USD), price and gross margin (%). They are: ABS Protection GmbH, Mammut, Clarus Corporation, Backcountry Access, Scott, Ortovox, ARVA, Osprey Packs, The North Face, Dakine, Mystery Ranch, Millet(Calida Group), Motorfist, Deuter,

On the basis of types, the market is primarily split into Mono Avalanche Airbags, Dual Avalanche Airbags

On the basis of applications, the market covers: Skiing, Climbing, Hiking, Others

On the basis of geography, the market covers: North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia etc.), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

How Far Does The Scope of This Research Study Traverse?

ACCESS FULL REPORT: https://marketandresearch.biz/report/91858/global-regenerative-medicine-market-2019-by-manufacturers-regions-type-and-application-forecast-to-2024

Key Market Dynamics: The global Regenerative Medicine market research report forecasts the latest market trends, development methods, and research methodologies. Several factors that are directly affecting the market such as the strategic production and methods, development platforms, and the product model, as well as the minute change within the product profile, are included in the report.

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team (sales@marketandresearch.biz), who will ensure that you get a report that suits your needs.

Ron is a very well known face in the journalism world. He is the editor-in-chief of Top News Herald. He covers Business news for Top News Herald. He lives in Buffalo New York with his wife Melinda.

See more here:
Global Regenerative Medicine Market 2019 Worldwide Industry Analysis to 2024 - Top News Herald

Read More...

BIOSTEM TECHNOLOGIES, INC. ANNOUNCES CORPORATE UPDATE; RESIGNATION OF CHAIRMAN AND CEO, APPOINTMENT OF INTERIM CEO AND CHARIMAN; BOARD INITIATES…

November 3rd, 2019 12:45 am

POMPANO BEACH, FL, Oct. 29, 2019 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC/PK:BSEM) today announced Henry Van Vurst would be stepping down as the company's Chief Executive Officer and as Chairman of the Board of Directors, effective October 22, 2019. Henry is yielding the position to focus on sales and business development for the companys life sciences division. The BioStem Board of Directors has elected Jason Matuszewski, a co-founder and longtime member of the executive team, as the company's interim Chief Executive Officer and Chairman, effective October 22, 2019.

"The Board of Directors of BioStem Technologies has accepted Henrys decision to step down as CEO and Chairman to focus on business development and sales, said Jason Matuszewski. Matuszewski continued, as one of the founders of BioStem Technologies, I have a profound commitment to the success of our company and to ensure the continual focus of our vision and the execution of our strategy. I am fully invested in reassuming the role of CEO until such a time that this important responsibility can be transitioned to the right person following a systematic search that will allow us to maintain our focus on our important fourth quarter.

The company also announced the expansion of its leadership team with the addition of Ken Warrington, PhD as Senior Vice President of Operations. Dr. Warrington brings significant expertise in biopharmaceutical product development and cGMP production. Dr. Warrington will play a key role in the expansion of the laboratory production and development initatives as BioStem continues to accelerate its growth of the BioStem Life Sciences division.

About BioStem Technologies, Inc.(OTC PINK: BSEM):BioStem Technologies, Inc.is a global life sciences corporation, providing innovative technologies with a concentration in Regenerative Medicine. The companys mission is to discover, develop and produce the most effective Regenerative Medicine products in the world. The company is comprised of a diverse group of scientists, physicians, and entrepreneurs who collaborate to create innovative products. These technologies improve the Quality of Life for our patients and, as a result, drive shareholder value.

BioStem Life Sciences, Inc.A company focused on the development of the highest quality birth tissue products for multiple sectors of healthcare. BioStem Life Sciences offers a comprehensive portfolio of high quality brands that include Rheo, Vendaje and Vendaje Optic. BioStem Life Sciences also provides leading class contract manfuactuing services to GMP and GTP standards for companies looking to develop birth tissue products, from bench top to comericalization. For the latest news and information about BioStem Life Sciences and its brands, please visitwww.biostemlifesciences.com

Forward-Looking Statements: Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "expects," believe" or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and additional risks factors as discussed in reports filed by the company with OTC Markets.

BioStem Technologies, Inc.Phone: 954-380-8342 Website: http://www.biostemtechnologies.com Email: info@biostemtech.comTwitter: @BiostemtechFacebook: BioStem Technologies

Investor Relations:Andrew Van Vurstinfo@biostemtech.com(954) 380-8342

The rest is here:
BIOSTEM TECHNOLOGIES, INC. ANNOUNCES CORPORATE UPDATE; RESIGNATION OF CHAIRMAN AND CEO, APPOINTMENT OF INTERIM CEO AND CHARIMAN; BOARD INITIATES...

Read More...

BioLife Solutions to Report Third Quarter 2019 Financial Results and Provide Business Update on November 12, 2019 – Yahoo Finance

November 3rd, 2019 12:45 am

BOTHELL, Wash., Oct. 31, 2019 /PRNewswire/ --BioLife Solutions, Inc. (BLFS), a leading developer and supplier of best-in-class bioproduction tools for cell and gene therapies, ("BioLife" or the "Company"), today announced that the Company's third quarter 2019 financial results will be released after market close on Tuesday, November 12, 2019, and that the Company will host a conference call and live webcast at 4:30 p.m. ET (1:30 p.m. PT) that afternoon. Management will provide an overview of the Company's financial results and a general business update.

Cell and gene therapy tools. (PRNewsfoto/BioLife Solutions, Inc.)

To access the webcast, log on to the Investor Relations page of the BioLife Solutions website at http://www.biolifesolutions.com/earnings. Alternatively, you may access the live conference call by dialing (844) 825-0512 (U.S. & Canada) or (315) 625-6880 (International) with the following Conference ID: 7207519. A webcast replay will be available approximately two hours after the call and will be archived on http://www.biolifesolutions.com for 90 days.

About BioLife Solutions

BioLife Solutions is a leading supplier of cell and gene therapy bioproduction tools. Our proprietary CryoStor freeze media and HypoThermosol shipping and storage media are highly valued in the regenerative medicine, biobanking and drug discovery markets. These biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death. Our recently acquired ThawSTAR family of automated cell thawing products and evo cold chain management system reduce therapeutic and economic risk for cell and gene therapy developers by reducing the potential of administering a non-viable dose. For more information, please visit http://www.biolifesolutions.com and follow BioLife on Twitter.

View original content to download multimedia:http://www.prnewswire.com/news-releases/biolife-solutions-to-report-third-quarter-2019-financial-results-and-provide-business-update-on-november-12-2019-300949616.html

The rest is here:
BioLife Solutions to Report Third Quarter 2019 Financial Results and Provide Business Update on November 12, 2019 - Yahoo Finance

Read More...

Stem Cell Therapy: What’s Real and What’s Not at California’s For-Profit Clinics – UCSF News Services

November 3rd, 2019 12:44 am

Many for-profit stem cell clinics advertise therapies that are not backed by science and may actually cause harm.

For-profit stem cell clinics have popped up around California in recent years, advertising that they can treat everything from arthritis to Alzheimers, without FDA approval.

They claim that injections of stem cells (naturally occurring blank slate cells that can grow into any type of cell) can help alleviate pain or illness by replacing or regenerating diseased tissue claims that are not supported by existing research. The procedures can cost thousands of dollars out-of-pocket, and regulators have warned that patients have developed tumors, suffered infections and even lost eyesight after unapproved procedures.

No one knows how many clinics there are, but California reportedly has more than any other state. We asked Arnold Kriegstein, MD, PhD, director of the UC San Francisco Developmental & Stem Cell Biology Program, about whats real and whats not in stem cell medicine.

How do these clinics operate?

There has been an explosion of so-called clinics offering stem cell treatments for a wide range of ailments, none of which have been shown to be effective. They are largely unregulated. Many clinics claim that they can treat untreatable illnesses like Alzheimer's disease, autism, muscular dystrophy, or stroke. The list is quite extensive.

The majority are using fat tissue for their stem cells, obtained through liposuction. These are usually autologous cells, which means that they are taking the patient's own tissue and extracting cells to re-administer to the same patient, usually through an intravenous route. In addition to fat cells, some clinics administer bone marrow stem cells or umbilical cord or placental stem cells, which come from unrelated donors.

The clinics often advertise through testimonials from patients who've received their therapies. Many of the conditions that the testimonials address are the kinds that normally improve or fluctuate over time, such as joint pain, low back pain, arthritis, or multiple sclerosis.

The problem is that patients will receive a treatment, and then, within a month or two, they'll notice that the aches and pains in the joints are improving, and they will attribute the improvement to the stem cell therapy, when in fact it would've happened regardless.

What is the risk of trying an unproven stem cell treatment?

Reports of physical harm have included infections and the development of tumors. When using cells that are not the patients own, umbilical cord cells for example, immune responses can occur often triggering inflammatory conditions.

In cases where stem cells have been delivered into the eye, blindness has been reported, and when they have been delivered to the central nervous system through lumbar puncture (spinal tap), adverse outcomes including serious infections of the central nervous system and tumors have occurred.

Then there's the emotional cost associated with raising false hope, and the financial loss that comes from exorbitant fees charged for ineffective, potentially harmful therapies.

Why arent there more legitimate stem cell therapies available?

Stem cells have been in the news so much over the last decade or so that I think it has created the impression that therapies are already on the market. The reality is that it is very early days for the science. The most interesting, most promising animal studies are only now beginning to be translated into clinical trials, and the process for approval of therapies takes many years and very few are likely to succeed.

Unfortunately, the public needs to be patient, but the good news is that potential treatments are progressing along the pipeline.

What are some examples of proven stem cell therapies?

For the last 50 years or so, there have been countless patients successfully treated with hematopoietic stem cells, commonly known as bone marrow transplants. This remains the prototype for how a stem cell therapy can work. Other successful examples include corneal stem cell grafts for certain eye conditions, and skin grafts for burn victims.

There are efforts to see if stem cells could successfully treat diseases like Parkinson's and diabetes, particularly type 1 diabetes. There are clinical trials testing whether stem cell therapy might work against macular degeneration, a blinding disease that is very common as people age. There are also early stage clinical trials for nervous system disorders including stroke, spinal cord injury, and ALS (Lou Gehrigs disease).

All of these examples are still at a very early stage, where the primary goal is to make sure that the approaches are safe. To determine if they are effective will require large, well-controlled, relatively long-term clinical trials.

What will it take to advance stem cell therapy into more real treatments?

This is where basic research comes in. The field is evolving quickly, there's much to be done, and there's still a huge amount of promise in stem cell therapies down the road. But it's going to take a lot of very careful and very laborious research before we get there.

Read more here:
Stem Cell Therapy: What's Real and What's Not at California's For-Profit Clinics - UCSF News Services

Read More...

Shelter animals receive care at ISU College of Veterinary Medicine on their way to adoption News Service Iowa State University – Iowa State…

November 2nd, 2019 12:45 am

AMES, Iowa In the real world, win-win scenarios are rare and often too good to be true. But the Iowa State University College of Veterinary Medicine has pulled off an even more elusive win-win-win by providing health care to thousands of shelter animals on their way to being adopted.

ISU veterinary students win by getting experience treating live animals, and animal shelters win by saving money through the free program. The biggest winners in the equation, however, are the shelter animals, who receive a clean bill of health and usually end up being adopted into loving homes.

The ISU College of Veterinary Medicine offers a surgery, anesthesia and community outreach course as a semester-long program for third-year veterinary students, with an option for extending the course for an additional semester. Students in the course gain hands-on experience admitting patients, screening them for a wide range of health problems and performing common procedures on the animals, such as spays and neuters.

Were helping the shelters move animals through their program so their length of stay is decreased, said Dr. Joyce Carnevale, a clinical assistant professor of veterinary clinical sciences who coordinates the community outreach portion of the program. A dog or cat that receives care in our program can get adopted more readily.

More than 300 animals, mostly cats and dogs, receive care over the course of a semester. Since the program began in 2016, more than 2,000 animals from more than 20 shelters, welfare organizations and animal rescues have gone through the program. The animals come not only from Iowa but Texas, Illinois, Missouri and beyond. And nearly all of the animals that receive care through the program wind up getting adopted, said Dr. Tamara Swor, a clinical assistant professor of veterinary clinical sciences who leads the surgery and anesthesia portions of the program.

From left, third-year veterinary medicine students Sami Naberhaus, Katie Griger and Monique Reid tend to George, a boxer-heeler mix, in the recovery room following surgery. Photo by Christopher Gannon. Larger image.

On a recent afternoon in early October, a frenzy of activity unfolded in three different rooms inside the ISU College of Veterinary Medicine. In an exam room, veterinary students checked in and performed routine health screenings on several dogs. These routine procedures include blood draws and heartworm checks on dogs older than six months. Its the first step in a process that takes five or six days during which every animal that enters the program undergoes a comprehensive health assessment, Carnevale said. The program treats all common problems presented in shelter pets, including eye, ear and skin problems and gastrointestinal parasites, she said.

A few rooms over, eight surgical teams prepared dogs to be neutered. Each team consisted of three students: a lead surgeon, an assistant surgeon and an anesthesiologist. The surgical teams rotate roles throughout the semester, ensuring each student gets a well-rounded experience. The students performed pre-operation checks on the dogs and anesthetized them, giving the animals comforting pats, rubs and ear scratches to put them at ease as much as possible.

Once a surgical team successfully anesthetized their dog, they wheeled the animal next door into an operating room with more than a dozen surgical stations. Each station comes equipped with individual monitors that offer constant updates on the patients vitals, as well as individual anesthesia machines. The surgeons scrubbed in to ensure everything remained sterile and then began their procedures.

Over the next hour or so, the student surgical teams completed their procedures to the steady beeps of the monitors. ISU veterinary faculty roamed the operation room, fielding occasional questions from students and monitoring the procedures.

Clinical assistant professor Joyce Carnevale holds Ernie, a shelter dog, while other dogs are prepared for surgery by third-year veterinary students at the ISU College of Veterinary Medicine. Photo by Christopher Gannon. Larger image.

DaKota Tilleraas, a third-year veterinary student from Hastings, Minnesota, said the program helps students develop skills theyll need as practicing vets. The physical exams, spays and neuters that make up a large portion of the semesters clinical work are the bread and butter of practicing veterinarians, Tilleraas said, and getting experience on live animals benefits the students immensely.

Earlier this semester, as Tilleraas prepared to perform her first spay as a surgeon on a cat, she learned one of her classmates had adopted the animal. That first procedure causes many students anxiety, and Tilleraas said she felt even more tension knowing her classmate would take the cat home.

So that was a little more pressure for me getting to do my first spay and then knowing shes already adopted by one of my classmates, Tilleraas said.

But the procedure went smoothly and her classmate was pleased with the results, Tilleras said.

Aislinn Ophoff, a third-year veterinary student from Terre Haute, Indiana, said her first spay on a cat went smoothly as well. So did her work as an anesthetist for a neuter, also on a cat. She said the course gives students a chance to work with cats and dogs of varying breeds, sizes and temperaments, mirroring the experiences of practicing veterinarians.

This is really helpful in giving us just the hands-on skills, clinical experience that you dont get when youre sitting in a classroom from nine to five, Ophoff said.

Ophoff also said she appreciated being able to perform the procedures under the watchful eye of faculty, who offer feedback and constructive criticism that helps the students improve.

The animal shelters benefit from the program as well, said Julie Taylor, shelter manager of the PAWS Humane Society in Charles City, which has sent animals to Iowa State for years. Taylor said the animals shes seen go through the ISU program have all received high-quality care. And the comprehensive nature of the program, from preventive health screenings to blood tests to spays and neuters all free of charge saves money for shelters and gives prospective pet owners peace of mind.

Its great to have all those details on an animal taken care of, and then at no cost. Thats huge, Taylor said.

More here:
Shelter animals receive care at ISU College of Veterinary Medicine on their way to adoption News Service Iowa State University - Iowa State...

Read More...

WARF donates $15 million to expand UW School of Veterinary Medicine – The Badger Herald

November 2nd, 2019 12:45 am

The Wisconsin Alumni Research Foundation recently donated $15 million for expanding the current University of Wisconsin School of Veterinary Medicine.

The expansion comes after six years of planning, according to Mark Markel, the Dean of the School of Veterinary Medicine.

SVM was built 35 years ago. About four years ago, the class size of the veterinary school increased from 80 to 96. When the next years incoming class is admitted, SVM will be fully expanded in terms of student capacity, leading to severe space constraints, Markel said.

Previously, the UW Veterinary Care clinics saw about 12,000 patients a year. Now, they see 28,000, leading to severe overcrowding, Markel said.

Rachel McNally, UW veterinary medical student, said the facility doesnt have the capacity to treat as many patients as they would like to.

UW claims Apple violated patent, US Supreme Court declines to hear caseThe U.S. Supreme Court declined to hear a patent case filed by the University of Wisconsin against Apple on Monday. Read

Its great that we have this expansion so we can reach more of our clientele and provide them with better care, McNally said.

Markel said the current space places constraints on teaching and learning spaces, and the new building will allow improvement on those items, particularly the hospital but also conference rooms.

Diana Lewis, UW veterinary medical student, said current students wont get to experience the immediate benefits of the expansion, but is excited for future students who will benefit.

I am really excited [because] we are super cramped for space here, Lewis said.

About five years ago, SVM conducted a feasibility study to determine the need for a new building across the street, Markel said.

SVM worked with legislators, campus leadership, University system leadership and Gov. Tony Evers in regards to this project. July 3, SVM was granted $90 million and needed to raise another $38 million. Previously, the school raised between $25 and $26 million, and the addition of the WARF gift of $15 million puts the SVM over the $38 million they had to raise, Markel said.

The equipment the building is going to require is expected to be an additional $10 million, according to a UW News article.

According to Markel, the project received $90 million in state funding, SVM raised about $25 million and WARF donated $15 million, with the project budget about $128 million.

Construction is set to begin in Spring 2021 and is projected to be completed in two years. Renovations of the current building will be completed by 2024, according to UW News.

The Small Animal Clinic will be expanded on the first floor and will be double the size it currently is. The Morrie Waud Large Animal Hospital will be remodeled, including a new cover arena and large animal isolation facility. The second floor will be a laboratory, conference rooms, graduate student offices and faculty offices. Markel said the third floor will be an infectious disease research space.

Make your own path: Panel of food-based executives offer advice to beginning entrepreneursAs part of the Wisconsin Alumni Research Foundations Entrepreneurons series, WARF hosted three food-based entrepreneurs in a panel to discuss Read

The parking ramp on Observatory is under construction because the workers cant build unless space is available for parking. Veterinary students, like Lewis, claim parking space constraints often provide various difficulties other than not having a place to park a car.

Its a stressor for people. Sometimes people bring in dogs or bigger animals that cant walk. We do have carts that can get them into the building but there is a little bit of a strain there, Lewis said.

SVM experienced severe equipment shortages over the years. The original building did not have MRI units and CT scanners in the clinics. The clinic was able to fit a CT scanner but it cannot be easily accessed. The MRI unit is in a trailer outside, Markel said.

To get our animals scanned and on the MRI unit we have to anesthetize them in this building take them through about a hundred yards of corridors outside, so in the winter thats through snow, Markel said.

During the remodel, the MRI unit will be brought inside. The clinic pathology department will move into the new building, freeing up space in the current building. That space will likely accommodate the cancer center due to the large number of patients seen each year, Markel said.

Exam rooms have sign up sheets because there are not enough exam rooms available for the amount of appointments. There are only three computers in the neurology ward which makes looking up records or information about clients and patients in a timely manner difficult, said McNally and Lewis.

The surgery suite also has space constraints. When teaching about radiographs or diagnostics, faculty and students are huddled around one computer said Lewis and McNally.

Its hard to learn under current space conditions, McNally said.

Clients and patients have also been affected by these space constraints.

Sometimes you have to wait multiple months to get the initial patient appointment because they can only see so many patients in a day, Lewis said. I am amazed that we can fit as many appointments in a day that we can.

There is a push to teach students and faculty how to make the clinic a comfortable space for pets and clients, they said, which can often be difficult with the high volume of patients and minimal space.

McNally said there should be an area in the new building to for pets to relax and quieter places for them to recover after procedures.

Its really hard to be a fear free space when there is so much noise and so much going on because were such a busy facility, McNally said.

The WARF gift will buy new equipment, but students like McNally are excited about the little things such as chairs, computers and phones that will improve the quality of patient care.

The current building does not have many windows or courtyard spaces, McNally said, and this can affect the mental health of the clients and patients. The new building will have plenty of these additions.

Little things can make our ability to provide care that much easier and that much higher quality that it can make such a huge difference, McNally said.

Continue reading here:
WARF donates $15 million to expand UW School of Veterinary Medicine - The Badger Herald

Read More...

Canine cancer screening test in the works – VeterinaryPracticeNews.com

November 2nd, 2019 12:45 am

Suggested Veterinary Products

Dentistry, Food & Nutrition

Veterinarians may soon be equipped with a tool that would assist in the early detection of canine cancer.

Veterinary oncologists at the Texas A&M College of Veterinary Medicine & Biomedical Sciences (CVM) are set to begin testing Nu.Q by VolitionRx, a suite of routine blood tests for the unique nucleosomes that serve as biomarkers in cancer.

The goal of this project with Volition is to provide all veterinarians with simple, affordable, routine blood tests that can help identify disease early and improve the lives of both animals and the people who love them, says Eleanor M. Green, DVM, Dipl. ACVIM, Dipl. ABVP, the Carl B. King dean of veterinary medicine.

The research will be led by Heather Wilson-Robles, DVM, DACVIM, associate professor and Fred and Vola N. Palmer chair in comparative oncology at the CVM.

I am excited to be working with Volition on this project, Dr. Wilson-Robles says. The Nu.Q platform has the potential to change the landscape of veterinary cancer diagnostics and provide much needed affordable and reliable screening tests that, to date, simply dont exist in the veterinary world.

Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life, Texas A&M says, adding that 25 percent of the more than 55 million dogs in the U.S. are expected to develop cancer at some stage of their life.

Visit link:
Canine cancer screening test in the works - VeterinaryPracticeNews.com

Read More...

This Veterinary Technician Is Obsessed with Teeth – Tufts Now

November 2nd, 2019 12:45 am

Kate Zukowski, a certified veterinary technician at Tufts at Tech Community Veterinary Clinic, has a passion for your pets pearly whites.

Veterinary technicians are the nurses of veterinary care, and many go through rigorous specialty training to better serve clients. Zukowski recently became certified for dentistrya professional calling that began many years ago.

Before arriving at Tufts five years ago, Zukowski spent fifteen years at a busy, multi-doctor veterinary practice in Shrewsbury, where she had the opportunity to work in pretty much every department. I was very interested in anesthesia and surgery, and then dentistry, she said. I kind of just ran with the dentistry part. (Read Five Ways to Keep Your Pet's Teeth Healthy with advice from Zukowski.)

Noticing a need for higher-quality dental care, she spent hundreds of hours trainingporing over complex cases and attending conferencesto become a veterinary technician specialist in dentistry.

Having Kate here as a technician with the high specialty interest in dentistry makes the entire dental service here at Tufts at Tech better and easier on the doctors, says veterinarian Gregory Wolfus, V98, who oversees the clinic, which is based at Worcester Technical High School and run by Cummings School of Veterinary Medicine at Tufts University. Once we figured out the gift that Kate brought with her, it very quickly pigeonholed her in a position that 80 percent of her time is doing dental work. Shes the first and only boarded dental technician in New England at this point.

So far, Zukowski has assisted on some interesting cases, including a root canal for a police dog and oral surgery on a red fox. The nearby Southwick Zoo once called on her and Wolfus to do dental work on a ring-tailed lemur and a patas monkeyand did you know dogs can wear braces?

However, most clients at Tufts at Tech have more common issues, such as periodontal disease and fractured teeth, as well as tooth resorption in cats. More than 80 percent of dog and cats over age three will be affected by periodontal disease, she said.

At Tufts at Tech, we see a lot of periodontal disease thats been neglected for a decade, Zukowski said. We see a lot of dogs and cats with horribly infected painful mouths and at the end, we've removed all of that and they are happy and pain-free. Every single one of those cases is important to me because we've made such a huge impact on the quality of life for those patients.

Tufts at Tech, which serves low-income pet owners, currently averages about 500 clients a month, with 15 to 20 dental procedures a month. For now, shes focused on the critical work of educating veterinary students at Cummings School to follow in her pioneering footsteps.

She and Wolfus collaborated on a week-long intensive dental training course in February for 100 veterinary students at Cummings. They taught students how to take dental x-rays, perform extractions, treat diseaseall procedures that the students may perform during their primary-care rotation at Tufts at Tech. The Dental Week course was the first of its kind at Cummings School, and such a success that theyre already planning another session.

If you have individuals who are willing to pour their heart and soul in bettering themselves so that they can information share and help, teach, and support others, aren't those the most important commodity of people? Wolfus said. Kate is not just information-sharing, she's a critical part of the veterinarian-teaching university.

Angela Nelson can be reached at angela.nelson@tufts.edu.

Here is the original post:
This Veterinary Technician Is Obsessed with Teeth - Tufts Now

Read More...

New Carpinteria veterinarian has special interest in birds, rodents and reptiles – Coastal View News

November 2nd, 2019 12:45 am

Carpinteria Veterinary Hospital on Walnut Avenue welcomed a new veterinarian this month, Dr. Amy Belanger. Belanger holds a doctorate from Texas A&M College of Veterinary Medicine and a bachelors in biology from the University of Arkansas at Fort Smith. In addition to caring for dogs and cats, Belanger also has a special interest in birds, rodents and reptiles.

Belanger was drawn to exotics as a child. I have always loved our small feathered, furred and scaled friends and had many exotic pets growing up, said Belanger. Peoples special bond and commitment to their pets, no matter their size or species, has always inspired me. They present unique challenges and often require creative thinking to solve problems. I believe any animal is entitled to good veterinary care no matter its species.

Born and raised in Austin, Texas, Belanger grew up surrounded by all kinds of animals, from hermit crabs and tortoises to cockatiels and horses. I spent as much time in the sun as possible enjoying the parks, rivers and springs around Austin, she said. Belanger was also a competitive tennis player and traveled the U.S. for tournaments.

Belangers mother is a veterinarian in Austin and for many years worked for the Austin Zoo. During that time, Belanger had the opportunity to help her mother with exams on lions, kinkajous, birds of prey and other exotic species.

I grew up having a strong appreciation for the highs and lows of the job, said Belanger, and the commitment required in order to excel. I knew I wanted to be a veterinarian for as long as I can remember. My mothers love of her work inspired me to pursue my own passion to help people and their pets. I cannot imagine myself in any other field.

For Belanger, there are many reasons to love being a veterinarian, but what she loves most is making meaningful lifelong connections with people and their pets I take great joy in guiding people through the struggles, delights and victories of animal ownership.

In Carpinteria, Belanger has found a community of people dedicated to caring for their animals. I could not be happier with the community I now serve, she said.

Read the original:
New Carpinteria veterinarian has special interest in birds, rodents and reptiles - Coastal View News

Read More...

Scientists are producing deadly zoonoses on this tiny German island – Big Think

November 2nd, 2019 12:45 am

On a small, unassuming German island called Riems lies one of the oldest virus research institutes in the world. And also one of the most dangerous.

The Friedrich Loeffler Institute is closed to the public. To access the island, approved visitors must first cross a small stretch of the Baltic Sea via a dam, which can be closed immediately in case of an outbreak. To enter the facility, they must take a shower and put on protective clothing. Inside, scientists study some of the world's most deadly viruses, including bird flu, Ebola and mad cow disease.

One of their many focuses is zoonoses, which are diseases that can be spread from animals to humans, or vice versa. But the facility was originally founded in 1910 to study foot-and-mouth disease. Over the following decades, the Friedrich Loeffler Institute was used for various purposes, including the development of chemical weapons during World War II, vaccine research during the Cold War, and the study of animal welfare and husbandry. It eventually earned the nickname the "island of plagues."

In 2010, the Friedrich Loeffler Institute completed construction on a series of new laboratories that are classified as biosafety level 4, one of the most dangerous distinctions. Today, there are only a handful of level-4 facilities worldwide.

Map of level-4 facilities

The institute is also one of only two facilities worldwide with the ability to conduct large-scale animal studies, such as with swine and cattle. Robin Holland, a student in the Veterinary Medical Scholars Program at the University of Illinois College of Veterinary Medicine, described her experience studying pathology at the Friedrich Loeffler Institute like this:

"I learned how these diseases are managed, controlled, and diagnosed in real-world scenarios, their prevalence globally, and their potential for economic impact if outbreaks were to occur in a nave population."

University of Greifswald

Holland also described the containment procedures at the institute.

"Alongside engineers and biorisk officers, I saw the massive infrastructure of the FLI, including HEPA filtration of exhaust air, room decontamination by dry fogging, waste water treatment, and carcass rendering to animal byproducts. I learned how the level 2 through 4 facilities are managed, protocols for containment in the event of an emergency, and how facilities are designed and personnel are trained in order to ensure thatespecially considering work with highly contagious pathogens such as FMDVall pathogens are contained within the facility."

Zoonoses pose a major threat to humans. From malaria to rabies, they account for about 60 percent of all infectious diseases contracted by humans, and the Centers for Disease Control and Prevention estimates that "3 out of every 4 new or emerging infectious diseases in people are spread from animals." But as scientists continue to study how to treat, prevent and contain these infectious diseases, it's also worth noting the threats they pose to animals.

"The animal toll has been much greater," neurobiologist and public health physician Professor Charles Watson from Curtin University told Abc.net. "When the Nipah virus broke out in Malaysia in the late 1990s there were relatively few human deaths but five million pigs had to be slaughtered in order to wipe it out."

One reason zoonoses are so deadly for animals is that some mysteriously don't hurt humans, even when we contract them.

"It is really unpredictable, however many viruses are successful because they do not kill their human hosts and therefore get better transmission from person to person."

From Your Site Articles

Related Articles Around the Web

Read more from the original source:
Scientists are producing deadly zoonoses on this tiny German island - Big Think

Read More...

Veterinarians are dying of suicide at high rates, and the U of M is addressing it – West Central Tribune

November 2nd, 2019 12:45 am

Kristen Capen, who graduated from the University of Minnesotas College of Veterinary Medicine in the spring, has seen the rough side of the profession. Euthanizing a beloved family pet is hard, she said, even if the animal is elderly or sick.

I feel bad for the family, especially if it's an older dog, if there are kids, if the dad is there, said Capen, who now works at an emergency animal hospital in Arizona. If everyone in the room is crying, sometimes I also cry, out of basically empathy for what they're going through.

Capen said the worst part of her job is when she has to euthanize an animal because the owner can't afford the care or isn't willing to take it on.

It's awful. There's no real way to describe it, she said. It's not murder. But it feels bad, and sometimes it feels wrong, even though it's the only option.

Experts say those stresses help explain why veterinarians have disproportionately high suicide rates. Female vets are three-and-a-half times as likely to die of suicide than the general population, and men are more than twice as likely, according to a study published this year by Journal of the American Veterinary Medical Association. The study also noted the total number of suicides among female veterinarians has been going up.

There are other complicating factors about the job. Being a veterinarian is one of those careers people dream of their whole lives; it can be disappointing to reach the goal and have it not look the way you imagined. Tuition at vet school is expensive, which means that people often graduate with loads of student debt. And vet salaries often dont keep pace with it.

Besides the headache of dealing with distraught or angry clients, the business model can be difficult to handle, too. While a physician in private practice usually has somebody to handle billing, scheduling, and other tasks, vet practices are often so small that the doctor is managing all of it. And while even general practitioners can refer their patients to specialists, veterinarians are often left doing the job of radiologist, orthopedist, dentist, and every other specialist for their patients.

Acutely aware of these challenges and the increased risk of suicide vet schools are trying to help.

Athena Diesch-Chham has been a clinical veterinary social worker at the vet school at the University of Minnesota for the last seven years. She works with students on both the daily stresses of being in veterinary school and in preparing coping skills for the job. (Diesch-Chham worked with Kristen Capen until Capen graduated last year.)

Some students are really struggling with I hate to say small but smaller stuff of I'm having a really hard day and I just need to get my emotions out, get re-regulated and then get back into class, Diesch-Chham said.

But especially by their fourth year, vet school students are starting to get a real taste of the stresses of the job. That can mean dealing with things like a euthanasia procedure the vet doesnt think needs to be done.

What I have really started to tell our students is, If you don't agree with it, don't do it, because what that does to your psyche and what that does to you emotionally, we're talking years of therapy, she said.

Veterinarian Suzanne Tomasi, an epidemiologist for the Centers for Disease Control and Prevention, did one of the recent studies that looks at veterinarian suicides. She's also looked at ways to prevent suicide. Some of it is pretty obvious work-life balance stuff, she said, like trying to schedule shorter work shifts.

Other suggestions are more industry-specific ways of making it harder for people with suicidal thoughts to actually hurt themselves. Because of their jobs, veterinarians have access to the chemicals used to put animals down, and studies have found they often use the drugs on themselves.

The other recommendation we've made is looking at checks and balances to help manage euthanasia solutions, Tomasi said.

Other people are working on this, too. There's an organization of veterinarians that runs a support group on Facebook. It just announced a partnership with a company to provide veterinarians with online counseling.

This reporting is part of Call to Mind, our MPR initiative to foster new conversations about mental health.

If you are having thoughts of suicide, call the National Suicide Prevention Lifeline at 1-800-273-8255 or go to SpeakingofSuicide.com for more resources.

Read more:
Veterinarians are dying of suicide at high rates, and the U of M is addressing it - West Central Tribune

Read More...

When It Comes To Diabetes, Control Is The Goal – KPAX-TV

November 2nd, 2019 12:44 am

When it comes to diabetes, control is the goal

More than 30 million people in the United States have diabetes, according to the Centers for Disease Control and Prevention . However, a quarter of them have not been diagnosed.

That matters because, when controlled, diabetes is a condition you can live with. However, to control it, you must know you have it.

Diabetes occurs when your hormones dont regulate blood sugar appropriately.

Type 2 diabetes is characterized by cells that dont respond to insulin as they should. They dont absorb glucose appropriately, leading to fatigue, weight loss, excessive thirst, frequent urination and itchiness. As the disease progresses, your body may produce insufficient levels of insulin.

Type 1 diabetes shows signs in childhood or early adulthood. Your pancreas does not make insulin, necessitating continuous insulin therapy to help the cells learn to use sugar effectively.

When you have diabetes, you face a lifelong balancing act of maintaining healthy blood sugar and insulin levels. It can be a struggle to keep that balance, which is why diabetes specialists, like those at the Providence Endocrinology, Diabetes and Nutrition Center, exist.

I tell every patient theyre the boss, and Im just here to help guide them, endocrinologist Meredith Roth says. I want to know what their goal is when they come in. For a patient, that might be them saying, Im ready to get my blood sugars under control, and I can help give them a framework and make that into an objective goal that we can work towards together.

Many of the techniques for controlling diabetes are similar to habits people should have, anyway, but some are unique.

Test your blood sugar

How often you need to test depends on the type of diabetes you have, how often you eat and exercise, how recently you were diagnosed, whether youre ill, and the medications you take. On average, you may test your blood sugar one to seven times a day, according to Everyday Health .

Eat a balanced diet

Avoiding processed foods and foods high in sugars or carbohydrates helps prevent blood sugar spikes. The better part of your diet should be made up of fruits, vegetables, fish, nuts, whole grains, and lean meats. Aim for snacks with high fiber, healthy fats, and protein.

Recognize the signs of low blood sugar

Low blood sugar, or hypoglycemia, happens when blood sugar levels fall below normal, usually anything less than 70 milligrams per deciliter. Symptoms include shakiness, abnormal nervousness, sweatiness, confusion, lightheadedness, a fast heartbeat, pale skin, hunger, tingling or numbness in your face, clumsiness, nausea, and hunger, according to the American Diabetes Association .

Maintain a healthy weight

The healthier your weight, the easier it will be to control blood sugar levels. If you need to lose weight, it doesnt have to be a dramatic amount, as WebMD reported. It takes only a seven percent loss to improve insulin sensitivity by 57%.

One simple way to cut calories and, therefore, pounds is to replace foods like white bread and pastries that are high in carbs but low in fiber. Choose healthy fats that come from foods like avocado, flaxseeds, canola oil and nuts.

For more information on how to control your diabetes, call or visit a Providence Health & Services location near you.

Read the original:
When It Comes To Diabetes, Control Is The Goal - KPAX-TV

Read More...

Nerve Damage in the Feet a Prominent Consequence of Diabetes – BioSpace

November 2nd, 2019 12:44 am

BETHESDA, Md., Nov. 1, 2019 /PRNewswire/ -- The American Podiatric Medical Association announced today a new public education campaign, Don't Lose Your Nerve to Diabetes. The campaign will educate the public about the importance of preventing diabetic peripheral neuropathy (nerve damage) before it happens and will underscore the critical role podiatrists play in treating diabetes and complications such as neuropathy.

Neuropathy is caused by blood sugar levels that get too high or too low, damaging the nerves that lead to the feet and preventing them from functioning properly. The result could be anything from intensely painful burning, tingling sensations to numbness and heaviness in the feet. Those who lose sensation altogether may not notice an injury or sore, which could lead to a serious infection. Numbness can also lead to balance problems or cause a fall.

Startling statistics indicate as many as 70 percent of people with diabetes suffer from neuropathy, and the nerve damage is most often permanent. Visiting a podiatrist regularly can help patients avoid peripheral neuropathy and address the symptoms if nerve damage does occur.

"Pain or numbness in your feet is never normal," said APMA President David G. Edwards, DPM. "What you can't feel can hurt you. Daily self-exams are critical for people with diabetes, but if you notice any changes in sensation in your feet, don't wait to see your podiatrist!"

The Don't Lose Your Nerve to Diabetes campaign, which takes place during November's Diabetes Awareness Month, features educational material geared toward the public and a depth of materials for health-care providers. To learn more about the campaign, and to find a podiatrist in your area, visit http://www.apma.org/diabetes.

The American Podiatric Medical Association (APMA) is the nation's leading professional organization for today's podiatrists. Doctors of Podiatric Medicine (DPMs) are qualified by their education, training, and experience to diagnose and treat conditions affecting the foot, ankle, and structures of the leg. APMA has 53 state component locations across the United States and its territories, with a membership of more than 12,500 podiatrists. All practicing APMA members are licensed by the state in which they practice podiatric medicine. For more information, visit http://www.apma.org.

Contact: Kevin Hessklhess@apma.org(301)-581-9221

View original content to download multimedia:http://www.prnewswire.com/news-releases/nerve-damage-in-the-feet-a-prominent-consequence-of-diabetes-300939938.html

SOURCE American Podiatric Medical Association

View post:
Nerve Damage in the Feet a Prominent Consequence of Diabetes - BioSpace

Read More...

Could Telehealth Save the Medicare Diabetes Prevention Program? – mHealthIntelligence.com

November 2nd, 2019 12:44 am

November 01, 2019 -With news that the Medicare Diabetes Prevention Program isnt drawing a crowd, lawmakers are urging federal officials to add telehealth to the program.

A group of 19 senators has written a letter to Health and Human Services Secretary Alex Azar and Centers for Medicare & Medicaid Services Administrator Seem Verma, asking them to make virtual care part of a Medicare-backed service that aims to improve health and wellness for roughly 84 Americans at risk of developing type 2 diabetes.

And theyre arguing that connected health could turn the program around.

A Medicare beneficiarys access to the life-improving program should not, and cannot, be determined solely by the zip code in which he or she lives, the senators wrote. Furthermore, lack of access for eligible beneficiaries has the potential to not only depress enrollment, but also to reduce potential cost savings.

CMS has done outstanding work developing online resources to show where MDPP suppliers are located, but these resources make clear that there are geographic regions where eligible beneficiaries lack reasonable access to a qualified supplier, the letter continues. Including virtual providers could empower these beneficiaries with feasible options for preventive, value-based care.

READ MORE: Brigham and Womens to Use Telehealth Platform in Dementia Study

The original Diabetes Prevention Program was developed by the National Institutes of Healths National Institute of Diabetes and Digestive and Kidney Disease (NIDDK), and focused on in-person classes and one-on-one coaching. Based on that model, which is administered by the Centers for Disease Control and Prevention, CMS created the National Diabetes Prevention Program for Medicare beneficiaries and launched that program in 2018.

But the Medicare model does not reimburse care providers for using telehealth or mHealth tools. And thats keeping a lot of healthcare providers and public health programs from adopting the program.

Some 70 healthcare providers are now listed on the CDCs DPP website, though only a handful have been recognized as offering proof that their online programs reach recognized benchmarks for activity and weight loss. A growing number of programs are using virtual care as a means of expanding the programs reach and making the most of limited resources, and theyre asking CMS to cover those services.

Federal officials have long argued that virtual programs havent proven enough value to be included as a covered resource. Acknowledging that pressure, CMS did announce plans to include a telehealth model as a demonstration project, but hasnt offered an update yet on that model.

In the event that your agency believes it needs additional authority to include virtual providers in the MDPP expansion, we request additional information on the statutory changes that would be necessary, the senators wrote. In the meantime, we also ask you to update us on the status of your consideration for a virtual MDPP demonstration. While our preference is the inclusion of virtual providers in the existing model expansion, if an additional demonstration project is required, we request information on the plan for the launch of this demonstration project.

READ MORE: CMS Under Pressure to Cover mHealth Tools for Diabetes Management

The senators have the support of the American Medical Association, which issued a statement backing the letter. This past January, the AMA launched its own lobbying effort in support of adding connected health resources to the program, arguing that digital health access to coaching and health and wellness resources could help roughly 84 million Americans avoid diabetes.

Although the DPP lifestyle change program has strong evidence to support its effectiveness in preventing type 2 diabetes, many of the 84 million patients with prediabetes arent able to participate in an in-person program, the AMA said in an article posted in January on the organizations website. Some patients may not have the time or resources to attend weekly or monthly classes, or they may prefer an on-demand interaction at their convenience. Digital health, and specifically virtual diabetes prevention LCPs (lifestyle change programs), offer a way to overcome those barriers and connect more patients with programs to improve their health.

Theres also support from the American Diabetes Association, which this past June unveiled a study that found that a DPP enhanced with digital health tools can engage participants for an extended period of time and encourage healthy behaviors, including sustained weight loss and lower blood pressure.

In its latest letter, the AMA urged federal officials to recognize the value of connected health in efforts to promote value-based care.

We recognize that scaling an ambitious new model takes time, the organization wrote. Early returns suggest that a few changes would expand the programs reach. Allowing Medicare patients to virtually access this program, as many patients with private insurance are doing, would benefit the most underserved and vulnerable patients, as well as those in remote areas, who cannot access the program without this option. Here is an opportunity for Medicare to encourage a practical use of digital health tools.

Read the original here:
Could Telehealth Save the Medicare Diabetes Prevention Program? - mHealthIntelligence.com

Read More...

Exposure to chemicals in plastic linked to increased risk of type 2 diabetes, study finds – FOX 10 News Phoenix

November 2nd, 2019 12:44 am

Study suggests BPA exposure make increase risk of type 2 diabetes

Researchers in the study said the link remained after adjusting for traditional diabetes risk factors.

MELBOURNE, Australia - A new study found that exposure to chemicals commonly found in plastics, food and beverage can linings and other consumer products may be associated with an increased risk of developing type 2 diabetes.

The study, conducted by Australian and French researchers published Wednesday in Environmental Health Perspectives, found associations between exposure to bisphenol A, commonly known as BPA, and the incidence of type 2 diabetes.

The same result was found for bisphenol S, a common BPA replacement known as BPS.

Researchers said the findings add to a growing body of evidence that indicates that these chemicals might play a role in increasing the risk of type 2 diabetes.

BPA is a chemical commonly used in the production of polycarbonate plastic and epoxy resins and is found in consumer products such as food and beverage containers and thermal cash register receipts.

Plastic bottles are shown in a file image. (Photo by Karol Serewis/SOPA Images/LightRocket via Getty Images)

The study tracked data from 755 people without diabetes over a nine year period. The participants BPA levels were tested at the start of the study and three years later.

Researchers found that those with higher levels of BPA in their fasted urine samples had a near doubling of the risk of type 2 diabetes, compared to those with the lowest average exposure. Additionally, the study found that those with detectable levels of BPS were also associated with an increased diabetes risk.

The link remained after adjusting for weight, diet and physical activity, researchers said.

The present study adds to the limited literature on the prospective relationship between BPA exposure and diabetes risk and contributes to the growing body of evidence that BPA exposure may be a risk factor for diabetes independent of traditional diabetes risk factors, the study authors note.

According to Professor Dianna Magliano, one of the study authors from the Baker Heart and Diabetes Institute in Australia, the association was not as strong as some other risk factors for diabetes such as obesity but there is mounting evidence to warrant caution.

I would advise people to use glass where they can or better quality plastic and if there is an alternative to BPA receipts such as electronic receipts, I think we should consider it, Magliano said.

Magliano said the study is one of the first to look at BPS as a substitute for BPA and further research is needed to confirm the results.

BPA has been used in food packaging since the 1960s, according to the U.S. Food and Drug Administration.

Some research has shown that BPA can migrate into food or beverages from containers that are made with the chemical. Concern of possible health effects on fetuses, infants and children led to a ban of BPA in baby bottles, sippy cups and infant formula packaging in the United States.

However, the FDA has said that BPA is safe at the low levels that occur in some foods and is continuing its review of ongoing research.

We cannot completely eliminate BPA. But we can live a bit cleaner, Magliano told the Sydney Morning Herald. Limit your exposure to crappy plastic. Buy decent water bottles. And chuck out your takeaway plastics.

This story was reported from Cincinnati.

See the original post:
Exposure to chemicals in plastic linked to increased risk of type 2 diabetes, study finds - FOX 10 News Phoenix

Read More...

Former MTV Host Doctor Dre’s Battle With Diabetes Resulted in Him Losing Much of His Vision, He Reveals – Atlanta Black Star

November 2nd, 2019 12:44 am

Andre Doctor Dre Brown, who used to co-host the music video show Yo! MTV Raps with Ed Lover,talked about having diabetes during a recent visit to ABCs Here and Now.

Dre was diagnosed with the disease in 2007, and he revealed that he lost much of his sight because of it.

Im a Type 2 diabetic who has lost his vision, he explained. I have a foundation called the Doctor Dre VIC, which is called the Visually Impaired Can Foundation, and basically Ive been going through a whole different resurgence of my life.

I stopped at one point, and now Im doing this, and through the blessings of the late, great Dick Gregory and some people hes known, Ive worked through different holistic doctors out there to change what goes in my body and actually work with trying to do the best. We can treat diabetes, added the 56-year-old.

Dre then said hes working on putting an event together for men, so they can do things like test their blood sugar to determine if theyre at risk of having diabetes.

He also said there will be performances there, and the whole idea behind the event is to get men to take their health seriously.

Without your health, youre not wealthy, said the Long Island, New York, native.

But even though Dre doesnt have full use of his sight, hes able to see on occasion. And he also said his issues with vision didnt come solely from diabetes.

I had my retinas reattached, so I really didnt go blind just from the diabetes but in the reattachment, he explained. I have what you call scar tissue behind my eyes, so when that kind of fluctuates my vision comes back.

At the end of his interview, Dre said hes looking to create an army of people to help better treat Type 2 diabetes. And before the discussion concluded, the former TV host gave one piece of simple but crucial advice.

Drink water, he urged. Thats the first big start.

Read this article:
Former MTV Host Doctor Dre's Battle With Diabetes Resulted in Him Losing Much of His Vision, He Reveals - Atlanta Black Star

Read More...

Everything You Need to Know About Diabetic Eye Disease – HealthCentral.com

November 2nd, 2019 12:43 am

Your eye health may be the furthest thing from your mind if you have diabetes, but what you might not know is that the disease can directly impact your vision. According to the Centers for Disease Control and Prevention, diabetic retinopathya vision complication from diabetes leading to damage or swelling of blood vessels in the retinais the most common cause of vision impairment and blindness in adults in the U.S. and by 2050 will affect roughly 14.6 million people.

That's not the only diabetes-related condition that can damage eye health. "Diabetic eye diseases can affect almost all parts of the eye and surrounding structures," says Matthew Gorski, M.D., a Northwell Health ophthalmologist at the Ophthalmology and Ocular Surface Center in Great Neck, NY. "The lens of the eye (where cataracts form) and the retina, the inside wallpaper where light rays are absorbed, are the most common areas where diabetes can cause eye problems."

Here, experts explain the main types of diabetic eye disease, the role glucose plays in the severity of these conditions, and most importantly, how people living with diabetes can protect their vision.

High blood sugar can damage the pancreas, harden blood vessels, and over time, increase your risk of heart attacks and kidney disease. But in addition to these health risks, glucose that spikes too high can also harm your sight. "Fluctuations of blood-glucose levels significantly affect vision in both the short term and long term," says Orlin Sergev, M.D., Ph.D., owner of Equilibrium Endocrinology & Diabetes Center in Ladson, SC.

"In the short term, both high and low blood-glucose levels (especially with sudden changes) can cause vision to become blurry [due to fluid moving in and out of parts of the eye]," he says. "Long-term mismanaged glucose affects the blood vessels in the retina, which can cause permanent vision damage, including blindness."

This is why it's important for people with diabetes to see their eye doctor at least every nine to 12 months even if they have no symptoms, says Dr. Gorski, as the earliest stages of diabetic eye disease can often be asymptomatic.

Think of DR as the gateway condition to all other diabetic eye diseases. "With DR, elevated blood-glucose levels progressively damage the vessels in the retina, leading to swelling and bleeding that ultimately damages vision," says Dr. Sergev. "The severity is usually dependent upon the length of disease and the level of [glucose] control."

So while high glucose levels initially wreak havoc on blood vessels surrounding the eyes, affecting your vision by increasing blurriness or interfering with your ability to distinguish between colors, it's the continuous swelling and leaking of these vessels that can lead to other conditions like cataracts, glaucoma, and DME (more on that below).

How many people are affected by DR? The overall prevalence of diabetic retinopathy in adults with diabetes in the U.S. is 28.5%. There's also a class of diabetic retinopathy called vision-threatening diabetic retinopathy, and that's about 4.4% of diabetic adults.

"This means almost one-third of all diabetics have some form of diabetic retinopathy, and about five percent of them are going to have it severely affect their vision," says Dustin French, Ph.D., associate professor of ophthalmology at Northwestern University Feinberg School of Medicine in Chicago.

Currently, there's no known cure for diabetic retinopathy. However, retinal specialists can preserve sight and may reverse vision loss from diabetic retinopathy through various methods. Those might include injecting medication into the back of the eye, performing laser procedures, and/or retinal surgery.

According to the Mayo Clinic, symptoms of DR include:

One of the most common eye conditions people with DR encounter (especially those with type 2 diabetes) is DME, which happens when uncontrolled blood sugar causes swelling of the retina, says Dr. French. This causes vessels in the eye to leak out or restrict blood flow, leading to a loss in the central-most part of your vision.

"Over time, this creates black spots in a person's vision as their vessels begin to deteriorate," says Dr. French. And while the thought of your vision being taken away can be terrifying, DME can be easily treated, says Dr. French. (Yet another reason to stay on top of those checkups.) Eye injections with anti-VEGF medications can manage the abnormal vessels and help prevent blindness. (OK, yes, they do require shots into your eye, but we can help you prepare for that.)

According to the American Academy of Ophthalmology, symptoms of DME include:

Even if you aren't dealing with conditions like DR and DME, it's important to get your eyes checked regularly to stay on top of other eye conditions like cataracts (a clouding of the eye lens) and glaucoma (a group of conditions that damage the optic nerve). "Cataracts are five times more frequent in diabetics and glaucoma is two to three times more frequent," says Dr. Sergev.

Although the link between diabetes and cataracts is still murky, Dr. French says cataracts or glaucoma are often diagnosed at the same time a person gets screened for diabetic retinopathy, and this diagnosis may be due to certain lifestyle risk factors (such as smoking, excessive alcohol intake, or obesity) in addition to being diabetic.

What's more, the symptoms of cataracts and glaucoma, like blurry vision, distortion, and other eyesight changes, can often overlap with more serious conditions like DR and DME. This is why in addition to maintaining your glucose levels, eating a well-balanced diet, and not smoking, people with diabetes should closely monitor their eye health with a yearly dilated eye exam to help decrease the chances of developing diabetic eye diseaseas well as get proper treatment for any eye issues that do arise as quickly as possible.

See more helpful articles:

9 Tips to Prevent Eye Problems When You Have Diabetes

Watch Out! Home Hazards for People With Diabetes

Here Come the Sunnies: The Best Shades for People With Diabetes

See original here:
Everything You Need to Know About Diabetic Eye Disease - HealthCentral.com

Read More...

Page 853«..1020..852853854855..860870..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick